Grant: New Investigator Salary Award - PA: Drug Safety and Effectiveness - Drug Safety
McGill University
$300,000.00
The Cardiovascular Safety of Varenicline: A Population-Based Cohort Study
FY 2011-12
Summary
Varenicline is a pill that is used to help people quit smoking. It is sold under the trade name Champix. Previous studies have shown that it is the most effective pill used to help people stop smoking. However, there is now some evidence that varenicline may have harmful effects on people's hearts and that it might increase the chances of having a heart attack. Government agencies like Health Canada and the U.S. Food and Drug Administration are currently studying the safety of varenicline. Unfortunately, available information about its safety is limited. For this reason, more studies are needed to determine if varenicline causes heart problems in people who are trying to stop smoking. The proposed study will examine the safety of varenicline using information from the General Practice Research Database, or GPRD. The GPRD is a database that contains the medical records for more than 11 million people in the United Kingdom. We will use the GPRD to identify two groups of patients: those who took varenicline and those who took bupropion. We will then compare the number of people in each group that had a heart attack in the 3 months after they started taking the pill. We will also check if varenicline increases the chances of dying or being hospitalized for a stroke, heart failure, or heart operations. To perform these comparisons, we will use a new type of statistical analysis called high-dimensional propensity scores. This study will take 2 years to complete. If varenicline increases the chances of having heart problems, patients and doctors need to know about these potential side effects. On the other hand, if varenicline is safe, they need to know so that it can be prescribed to help people stop smoking. Either way, this study will have important clinical and public health implications.
Department
Program
New Investigator Salary Award - PA: Drug Safety and Effectiveness - Drug Safety
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
241765
Name
Filion Kristian B
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Population and Public Health
Theme2
Social / Cultural / Environmental / Population Health
Prcname2
Health Research Salary A
Projecttitle
The Cardiovascular Safety of Varenicline: A Population-Based Cohort Study
Programtype2
Salary Programs
Orgnameinp2
McGill University
Cihramount2
$300,000
Cihrequipment2
$0
Programname2
New Investigator Salary Award - PA: Drug Safety and Effectiveness - Drug Safety
Keyworddelim
Cardiovascular Disease; Databases; Drug Safety; Myocardial Infarction; Pharmacoepidemiology; Side Effects; Smoking Cessation; Stroke; Varenicline
Abstract
Varenicline is a pill that is used to help people quit smoking. It is sold under the trade name Champix. Previous studies have shown that it is the most effective pill used to help people stop smoking. However, there is now some evidence that varenicline may have harmful effects on people's hearts and that it might increase the chances of having a heart attack. Government agencies like Health Canada and the U.S. Food and Drug Administration are currently studying the safety of varenicline. Unfortunately, available information about its safety is limited. For this reason, more studies are needed to determine if varenicline causes heart problems in people who are trying to stop smoking. The proposed study will examine the safety of varenicline using information from the General Practice Research Database, or GPRD. The GPRD is a database that contains the medical records for more than 11 million people in the United Kingdom. We will use the GPRD to identify two groups of patients: those who took varenicline and those who took bupropion. We will then compare the number of people in each group that had a heart attack in the 3 months after they started taking the pill. We will also check if varenicline increases the chances of dying or being hospitalized for a stroke, heart failure, or heart operations. To perform these comparisons, we will use a new type of statistical analysis called high-dimensional propensity scores. This study will take 2 years to complete. If varenicline increases the chances of having heart problems, patients and doctors need to know about these potential side effects. On the other hand, if varenicline is safe, they need to know so that it can be prescribed to help people stop smoking. Either way, this study will have important clinical and public health implications.
Competitiondate
201109
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Filion, Kristian B
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $300,000~ $0~